Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | LPL | P06858 | 7/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.34 |
| ▸ | EGFR | P00533 | 2/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | LIPE | Q05469 | 5/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.30 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15773786 | 0.77 | LPL (0.34) | LPLLIPGUCHL1 | |
| SCHEMBL13527502 | 0.77 | LPL (0.44) | LPLLIPGJAK2BTK | |
| SCHEMBL3930607 | 0.73 | LPL (0.38) | LPLLIPGEGFRJAK2BTK | |
| SCHEMBL476863 | 0.72 | LPL (0.36) | LPLLIPGEGFRJAK2BTK | |
| SCHEMBL29479006 | 0.71 | JAK2 (0.39) | LPLLIPGJAK2BTK | |
| SCHEMBL13098733 | 0.71 | JAK2 (0.39) | LPLLIPGJAK2BTK | |
| SCHEMBL29586872 | 0.70 | LPL (0.44) | LPLLIPGJAK2BTK | |
| SCHEMBL476862 | 0.70 | LPL (0.44) | LPLLIPGJAK2BTK | |
| SCHEMBL5899734 | 0.70 | LPL (0.54) | LPLLIPG | |
| SCHEMBL23803459 | 0.70 | LPL (0.36) | LPLLIPGEGFRJAK2BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411398-B1 | METHOD FOR MANUFACTURING A BORONIC ACID ESTER COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2014-12-17 | — | — | EP | disclosed |
| US-8785651-B2 | Method for manufacturing a boronic acid ester compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-07-22 | — | — | US | disclosed |
| US-20120123122-A1 | METHOD FOR MANUFACTURING A BORONIC ACID ESTER COMPOUND | GENENTECH, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| EP-2411398-A1 | METHOD FOR MANUFACTURING A BORONIC ACID ESTER COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010110782-A1 | METHOD FOR MANUFACTURING A BORONIC ACID ESTER COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120123122-A1 | METHOD FOR MANUFACTURING A BORONIC ACID ESTER COMPOUND | NISCH, BRSK1, BLK | BRD4 158/4885LPL 1463/4885LIPG 3166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.